Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$22.71M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
85.52%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
$2.242M
Q3 2024
Book Value
$1.665M
Q3 2024
Cash
Q3 2024
P/E
-0.3971
Nov 29, 2024 EST
Free Cash Flow
-$18.26M
TTM

Revenues

Revenues

Revenue YoY Change

No data

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Selling, General & Admin $13.44M $12.30M $10.97M $10.64M $8.700M $11.39M $3.020M $3.780M $870.0K
YoY Change 9.34% 12.07% 3.11% 22.3% -23.62% 277.15% -20.11% 334.48%
% of Gross Profit
Research & Development $17.62M $11.51M $8.608M $7.303M $1.967M $971.4K $289.9K $354.9K $200.0K
YoY Change 53.05% 33.72% 17.87% 271.27% 102.49% 235.05% -18.3% 77.44%
% of Gross Profit
Depreciation & Amortization $15.00K $25.58K $22.53K $22.78K $13.07K $5.885K $3.242K $862.00 $0.00
YoY Change -41.35% 13.5% -1.07% 74.27% 122.09% 81.52% 276.1%
% of Gross Profit
Operating Expenses $31.08M $11.51M $8.608M $7.303M $1.967M $971.4K $289.9K $354.9K $1.070M
YoY Change 169.99% 33.72% 17.87% 271.27% 102.49% 235.05% -18.3% -66.83%
Operating Profit -$31.08M -$23.83M -$19.60M -$17.96M -$10.68M -$12.36M -$3.312M -$4.132M
YoY Change 30.4% 21.58% 9.13% 68.14% -13.6% 273.26% -19.84%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Interest Expense $215.1K $90.10K $5.130K $20.00K $37.98K $1.890K $0.00
YoY Change 138.75% 1656.34% -74.35% 1909.63%
% of Operating Profit
Other Income/Expense, Net -$8.798K -$1.810K $0.00
YoY Change 386.08%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

No data

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Pretax Income -$30.86M -$23.74M -$19.60M -$17.94M -$10.65M -$12.37M -$3.310M -$4.130M -$1.070M
YoY Change 29.99% 21.15% 9.23% 68.45% -13.9% 273.72% -19.85% 285.98%
Income Tax $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$30.86M -$23.74M -$19.60M -$17.94M -$10.65M -$12.37M -$3.314M -$4.132M -$1.070M
YoY Change 29.99% 21.15% 9.21% 68.4% -13.88% 273.32% -19.8% 286.18%
Net Earnings / Revenue
Basic Earnings Per Share -$22.56 -$0.50 -$0.44
Diluted Earnings Per Share -$22.56 -$0.50 -$416.1K -$505.1K -$664.4K -$898.3K -$253.8K -$255.1K -$66.09K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

No data

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

No data

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

No data

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

No data

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Cash & Short-Term Investments $6.738M $20.95M $38.63M $27.32M $2.000M $8.600M $160.0K $1.600M $230.0K
YoY Change -67.85% -45.76% 41.39% 1266.0% -76.74% 5275.0% -90.0% 595.65%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $794.1K $484.2K $511.4K $380.0K $170.0K $240.0K $20.00K $40.00K $20.00K
YoY Change 64.0% -5.31% 34.57% 123.53% -29.17% 1100.0% -50.0% 100.0%
Inventory $3.010M $800.0K
Prepaid Expenses
Receivables $0.00 $34.85K $0.00 $0.00 $0.00 $10.00K $10.00K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $7.532M $21.47M $39.14M $30.72M $2.980M $8.850M $190.0K $1.640M $250.0K
YoY Change -64.92% -45.14% 27.41% 930.87% -66.33% 4557.89% -88.41% 556.0%
Property, Plant & Equipment $7.860K $23.03K $48.61K $40.00K $40.00K $20.00K $10.00K $10.00K $0.00
YoY Change -65.87% -52.62% 21.53% 0.0% 100.0% 100.0% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $21.82K $8.690K $10.00K $20.00K $20.00K $760.0K $30.00K $0.00
YoY Change -54.17% 151.09% -13.1% -50.0% 0.0% -97.37% 2433.33%
Total Long-Term Assets $3.139M $3.612M $3.722M $650.0K $550.0K $420.0K $1.070M $270.0K $160.0K
YoY Change -13.1% -2.96% 472.63% 18.18% 30.95% -60.75% 296.3% 68.75%
Total Assets $10.67M $25.09M $42.86M $31.37M $3.530M $9.270M $1.260M $1.910M $410.0K
YoY Change
Accounts Payable $1.398M $442.9K $973.2K $190.0K $440.0K $300.0K $630.0K $290.0K $20.00K
YoY Change 215.54% -54.49% 412.21% -56.82% 46.67% -52.38% 117.24% 1350.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $260.0K $70.00K $90.00K $200.0K $0.00 $0.00
YoY Change -100.0% 271.43% -22.22% -55.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.254M $2.810M $1.585M $450.0K $510.0K $390.0K $830.0K $290.0K $20.00K
YoY Change 15.8% 77.27% 252.29% -11.76% 30.77% -53.01% 186.21% 1350.0%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Total Liabilities $3.254M $2.810M $1.585M $450.0K $510.0K $390.0K $830.0K $290.0K $20.00K
YoY Change 15.8% 77.27% 252.29% -11.76% 30.77% -53.01% 186.21% 1350.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

No data

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Basic Shares Outstanding 1.368M 47.95M 47.10M
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

No data

Dividends

Dividends

No data

Stock Price

Market Cap: $9.0186 Million

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 26 full-time employees. The company went IPO on 2018-03-29. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. The company conducts preclinical research to explore how REQORSA may be administered in other solid tumors.

Industry: Pharmaceutical Preparations Peers: Black Diamond Therapeutics, Inc. Harvard Apparatus Regenerative Technology, Inc. Cardiff Oncology, Inc. Cyteir Therapeutics, Inc. Equillium, Inc. iBio, Inc. Passage BIO, Inc. TCR2 THERAPEUTICS INC.